Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.58 USD | +4.64% | +10.71% | -85.74% |
Apr. 17 | Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating | MT |
Apr. 16 | Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-85.74% | 82.93M | |
+28.50% | 662B | |
+22.23% | 546B | |
-4.93% | 359B | |
+16.97% | 323B | |
+4.08% | 289B | |
+13.68% | 234B | |
+3.84% | 198B | |
-10.35% | 194B | |
+3.98% | 167B |
- Stock Market
- Equities
- MRNS Stock
- News Marinus Pharmaceuticals, Inc.
- RBC Downgrades Marinus Pharmaceuticals to Sector Perform From Outperform, Slashes Price Target to $3 From $24, Keeps Speculative Risk